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INTRODUCTION
Anti -aminoacyl - tRNA synthetase (ARS) antibodies are one of
the myositis -specific autoantibodies. They include anti -Jo-1, PL-
7, PL-12, OJ, EJ, KS, Zo and Ha antibodies that are mainly identi-
fied in the sera of the patients with polymyositis (PM)/dermato-
myositis (DM) (1, 2). Anti -ARS antibody-positive cases complicate
interstitial lung disease (ILD) at a high rate together with or
without muscle symptoms and joint symptoms, which is called as
anti -synthetase syndrome (ASS). In some cases with ASS, ILD is
the only manifestation of the disease. It is reported that the con-
nective tissue diseases, including ASS, often develop in combina-
tion with other connective tissue diseases in one patient (i.e. PM/
DMwith systemic sclerosis), although the detection and diagnosis
of those diseases are difficult in many cases. Here, we report a rare
case that the ASS diagnosed in a patient with rheumatoid arthritis
(RA).
CASE REPORT
A 65-year-old female had been diagnosed as RA in the previous
hospital at the age of 57, and had started to receive bucillamine
(BUC) and methotrexate (MTX). Afterwards, she had developed
interstitial pneumonia (IP) of which the etiology was suspected to be
MTX-related, therefore the MTX treatment was discontinued and
IP was partly improved. Further, she developed nephrotic syn-
drome at the age of 59, and the result of renal biopsy suggested the
possibility of membrane nephropathy due to BUC. She also discon-
tinued to take BUC, and alternatively started to take 10 mg of
prednisolone (PSL) and cyclosporin A (CyA). After two years,
gradual deterioration of IP was observed, and she was referred to
our hospital. We reconfirmed the diagnosis of RA based on 2010
American College of Rheumatology/European League Against
Rheumatism (ACR/EULAR) rheumatoid arthritis classification
criteria (3), as she had 11 or more joint involvement, highly posi-
tive of anti -cyclic citrullinated peptide (anti -CCP) antibody and
rheumatoid factor (RF), and elevated C-reactive protein (CRP).
Moreover, the joint ultrasonography showed the synovial thicken-
ing and fluid accumulation in her both hands. The deteriorating IP
was considered to be RA-associated. Thus, the dose of PSL was
increased to 30 mg, which was gradually decreased afterwards, and
the dose of CyA was re-adjusted. With this treatment, she was free
from disease progression for about four years.
However, she started to feel worsening exertional dyspnea trig-
gered by the acute bronchitis, and was emergently admitted owed to
severe hypoxemia two weeks later. On her admission, physical
examination showed a body temperature of 37.3, heart rate of
100 beats per minute, a blood pressure of 101/74 mmHg, SpO2
92% on 8 L/min oxygen with a mask. Chest auscultation revealed
fine crackles on both sides with no murmurs of heart sound.
Chest X-ray showed ground-glass opacities (GGOs) and consoli-
dations in both lung fields (Figure 1). In the chest computed to-
mography (CT), diffuse pan- lobular GGOs with slight consolida-
tions along with bronchovascular bundle were newly observed in
addition to reticular shadows which had been recognized only in
subpleural areas from a year ago (Figure 2A, B). Laboratory find-
ings were as follows : white blood cell counts, C-reactive protein
(CRP), sialylated carbohydrate antigen Krebs von den Lungen-6
(KL-6), serum surfactant protein (SP)-A, and SP-D were elevated.
Anti -nuclear antibody, anti -centromere antibody, anti -CCP anti-
body, RF, and anti -ARS antibody were positive (Table 1). Soon
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after, she required the high flow nasal cannula oxygen therapy with
oxygen flow to 50L/min and FiO2 to 0.4. Under the diagnosis of the
acute exacerbation (AE) of pre-existing IP caused by an infection,
the administration of intravenous tazobactam/piperacillin (13.5 g
per day) , Levofloxacin(500 mg per day) and corticosteroid pulse
treatment (methylprednisolone 1 g per day for 3 days) followed by
0.5 mg/kg/day of PSL were started. This treatment improved her
general condition and chest CT findings (Figure 2C). She dis-
charged after the home oxygen therapy was introduced.
Because some auto-antibodies associated with acute/subacute
onset IP have recently become available in clinic, we examined
those including anti -ARS and anti -melanoma differentiation-asso-
ciated gene 5 (MDA5) antibodies after confirming that clinical ex-
amination with serum and sputum did not suspect the viral or
bacterial infections (i.e., Cytomegalovirus, Pneumocystis jirovecii,
etc.). The results showed that she was positive for anti -ARS and
PL-7 antibodies without any other auto-antibodies except for RF
and anti -CCP antibody (Table 1), indicating that IP in the present
case was caused by ASS although it is difficult to completely distin-
guish it from RA-associated IP with nonspecific interstitial pneu-
monia (NSIP) pattern. The characteristics in chest CT findings
showing GGOs and consolidations along with bronchovascular
bundle is more compatible to IP associated with ASS (4). In addi-
tion, her clinical course with frequent relapse and good response to
steroid therapy is consistent with IP with anti -ARS antibody (5).
Based on these findings, we diagnosed her as ASS combined
with RA.
DISCUSSION
We experienced a case of acute exacerbation of IP which was
considered to be associated with anti -PL-7 antibody-positive ASS
Figure 1. Chest X-ray of supine position on admission
Chest X-ray on admission showed consolidations in the bilateral lung.
Figure 2. Chest computed tomography
(A)Chest CT a year ago, when the activity of interstitial pneumonia was
stable, which showed a reticular shadow under the pleura.
(B) Chest CT on admission, which showed new bilateral ground-glass
opacities.
(C) Chest CT on 12 days after the treatments started, which showed
that the bilateral ground-glass opacities were improved.
Table 1 Laboratory data on admission
Hematology Serology
WBC 17300 /µl CRP 9.53 mg/dl
neu. 92.4 % ANA ×640
lym. 4.3 % β -D-glucan 6.0 pg/ml
mono. 2.7 % PR3 -ANCA ( -) U/ml
eos. 0.2 % MPO-ANCA ( -) U/ml
baso. 0.1 % KL-6 1735 U/ml
RBC 3.96 ×104/µl SP -D 341 ng/ml
Hb 11.5 g/dl SP-A 236.8 ng/ml
Ht 35.8 % anti -dsDNA Ab ( -)
Plt 31.4 ×104/µl anti -SS -A Ab ( -)
anti -Centromere Ab (+)
Biochemistry anti -CCP Ab 477 U/ml
AST 13 IU/l anti -RNP Ab ( -)
ALT 8 IU/l anti -Sm Ab ( -)
ALP 227 IU/l anti - Jo -1 Ab ( -)
LDH 13 IU/l anti -Scl -70 Ab ( -)
CK 41 IU/l anti -MDA5 Ab ( -)
T -bil 0.5 mg/dl anti -ARS Ab (+)
BUN 18 mg/dl anti -PL -7 Ab (+)
Cre 0.58 mg/dl RF 1354 IU/ml
Na 144 mEq/dl
K 5 mEq/dl Arterial Blood gas analysis(HFNCOT FiO2 0.5)
CL 106 mEq/dl pH 7.44
PaCO2 42.8 Torr
PaO2 79.6 Torr
HCO3 - 28.7 mmol/l
Abbreviations : Ab, antibody ; ALP, alkaline phosphatase ; ALT, alanine
aminotransferase ; ANA, anti -nuclear antibody ; ANCA, anti -neutrophil
cytoplasmic antibody ; ARS, anti -aminoacyl - tRNA synthetase ; AST, L-
aspartate aminotransferase ; BUN, blood urea nitrogen ; CK, creatine
kinase ; Cl, chlorine ; Cre, creatinine ; CRP, C-reactive protein ; eos,
eosinocyte ; Hb, hemoglobin ; HFNCOT, High flow nasal cannula oxygen
therapy ; Ht, hematocrit ; K, potassium ; KL-6, Krebs von den Lungen-
6 ; LDH, lactate dehydrogenase ; lym, lymphocyte ; mon, monocyte ;
MPO, myeloperoxidase ; Na, sodium ; neu, neutrophil ; Plt, platelet ; PR3,
proteinase 3 ; RF, rheumatoid factor ; SP, surfactant protein ; T-Bil, total
bilirubin ; TP, total protein ; WBC, white blood cell ; γ -GTP, γ -glutamyl
transferase.
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coexisting with RA.
RA patients with lung involvement are reported to mainly show
usual interstitial pneumonia (UIP) or NSIP pattern (6), and the
typical CT findings of chronic RA-related interstitial lung disease
(RA-ILD) have been reported as follows : GGO, honeycombing
shadow, linear/reticular opacities, centrilobular granular shadow,
septal thickening/pleural thickening and traction bronchiecsta-
sies are frequently observed, but the consolidation and broncho-
vascular bundle thickening are relatively rare (7). However, re-
garding acute or subacute-onset RA-associated IP, organizing
pneumonia (OP) and AE of pre-existing IP are common if infec-
tions and drug- induced lung injury are negligible (8). In the pre-
sent case, chest CT findings showed diffuse pan- lobar GGOs
which is consistent with AE of pre-existing IP, but not OP.
On the other hand, chest CT findings of patients with anti -ARS-
ILD were reported that : 1) the distribution of opacities was seen
predominantly in peripheral and/or peribronchovascular area (4),
2) the opacities with lower lobe-predominance often leaded the
lungs to lose their volume (so called “shrinking lung”) (9, 10), 3)
unlikely to form honeycombing shadow and centrilobular granular
shadow, 4) therefore the pattern of CT findings was considered to be
non-specific interstitial pneumonia (NSIP) pattern with or without
organizing pneumonia (OP) pattern.
In the chest CT findings of the present case, GGOs and slight
consolidations along with the pleura and broncovascular bundle
were more evident, and linear reticular shadow and traction bron-
chiectasis were observed with the lower lobe-predominance, how-
ever, honey combing shadow and centrilobular granular shadow
were not obvious. Firstly, we considered the acute exacerbation of
RA-IP, but there was reported that NSIP pattern of RA-IP have few
case of acute exacerbation (7). Considering the typical differential
patterns of IP among connective tissue diseases, CT findings in the
present case seemed to be more consistent with anti -ARS-ILD
rather than RA-ILD.
Moreover, the present case had twice AE of IP but relatively
good response to corticosteroids. Yoshifuji et al. reported that anti -
ARS antibody positive-ILD had a good response to corticosteroids,
but more frequently recurrence (5). This clinical course applies to
this case, and it is also one of the reasons why we diagnosed her as
anti -ARS-ILD.
Regarding the positivity of anti -ARS antibody in RA patients,
Nakashima et al. reported that anti -ARS antibodies were detected
in 30.8% of idiopathic inflammatory myopathy patients whereas
those were detected in only 4% of RA patients (11), suggesting that
the positive rate of anti -ARS antibody in RA patients is relatively low
(12-15). Currently, it is not known why anti -ARS antibodies be-
come positive in RA patients. Ishikawa et al. reported the case that
the treatment with TNF-α inhibitor was possibly the trigger to de-
velop ASS in an RA patient (15). Because the positive rate of anti -
ARS antibody in RA patients is low, more clinical experiences are
needed to elucidate the etiology of anti -ARS antibodies in RA pa-
tients. On the other hand, Nakajima et al. reported that, among 12
patients with inflammatory myositis accompanied with RA, 8 pa-
tients had IP and all of them had anti -ARS antibody (16). This
suggests that IP of RA patients may be associated with ASS rather
than with RA.
Among anti -ARS antibodies, the most frequently detected anti-
body is anti -Jo-1 antibody (approximately 30%), followed by the
others including anti -PL-7 antibody with the positive rate of 2-5%
(17, 18). In patients with anti PL-7 antibody, myositis and arthritis
may be less frequent and milder than in those with anti -Jo-1 anti-
body (19, 20). In this context, as it was the case in our patient, it
seems important to search for anti -PL-7 antibody in addition to
other anti -ARS antibodies in patients with ILD to detectan underly-
ing ASS, since this finding influences the treatment and prognosis of
the patient (21-23).
In conclusion, we experienced a case of IP which was consid-
ered to be associated with anti -PL-7 antibody-positive ASS in pa-
tient with RA. The careful examination is necessary to precisely
diagnose and treat the patients with RA-associated ILD as the sev-
eral etiologies may be overlapped in the same patient.
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